Rules vary by state and federal guidance for controlled substances
doi: 10.1111/j.1478-3231.2010.02439.x
Regulatory submissions will depend entirely on the final compilation of the TRIUMPH safety dossiers, meaning widespread commercial availability remains a future milestone
Wegovy (injectable semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) are some of the popular ones
Notably, retatrutide trials showed an overwhelming clearance of liver fat, with some cohorts experiencing up to an 80% reduction in hepatic lipid content, presenting a massive benefit for individuals dealing with metabolic dysfunction-associated steatotic liver disease (MASLD)
The authors received no financial support from pharmaceutical companies for the research, authorship, and/or publication of this article